Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs Omzo

FuturHealth
Graded #215

Higher grade

vs+11.399999999999991
Omzo
Graded #458

Lower grade

The verdict

FuturHealth takes it — 65.6/100 to 54.2/100.

FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFuturHealth +15
60
45
Dose & formulationFuturHealth +41
81
40
Clinical oversightOmzo +9
67
76
Labs & monitoringFuturHealth +9
61
52
FulfillmentOmzo +1
62
63
Contract termsEven
55
55
FuturHealth · left barOmzo · right bar

The numbers

MetricFuturHealthOmzo
WeighScore65.6/10054.2/100
GradeCC
Scorecard rank#215#458
Semaglutide$199/mo (compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Omzo

Graded #458 · C

Strengths

  • Compounded GLP-1 (semaglutide and tirzepatide) with clinician guidance
  • Free, discreet delivery on all treatments
  • FSA/HSA eligible
  • Multi-pillar: also women's hormone, sexual health, hair, skin, and daily health

Where it loses points

  • Pricing not published on the site — shown only after the intake quiz
  • Compounding pharmacy partner not named (states only 'independent state-licensed')
  • States of operation not published
  • Not LegitScript-certified (no certification displayed)
  • Legal entity not named; governing law given only as 'the state in which Omzo operates'

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard